Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XLF055 multiple-dose study in bacterial vaginosis
CTR20222591Phase 2Completed
- Sponsor
- Zhejiang Xinlifei Biotechnology
- Start
- Feb 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Bi-Live in bacterial vaginosis (BV), sponsored by Zhejiang Xinlifei Biotechnology. Started Feb 2023; status: completed.
02
Drugs
Bi-Live
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on CTR20222591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222591.